Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Profit After Tax (2016 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed Profit After Tax for 15 consecutive years, with -$99.1 million as the latest value for Q1 2026.

  • For Q1 2026, Profit After Tax fell 11.0% year-over-year to -$99.1 million; the TTM value through Mar 2026 reached -$422.6 million, down 163.46%, while the annual FY2025 figure was -$412.8 million, 161.27% down from the prior year.
  • Profit After Tax hit -$99.1 million in Q1 2026 for Agios Pharmaceuticals, up from -$108.0 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $947.9 million in Q3 2024 and bottomed at -$112.0 million in Q2 2025.
  • Average Profit After Tax over 5 years is -$24.8 million, with a median of -$91.8 million recorded in 2022.
  • Year-over-year, Profit After Tax plummeted 362.66% in 2023 and then surged 1137.97% in 2024.
  • Agios Pharmaceuticals' Profit After Tax stood at $36.5 million in 2022, then tumbled by 362.66% to -$95.9 million in 2023, then fell by 0.61% to -$96.5 million in 2024, then fell by 11.93% to -$108.0 million in 2025, then grew by 8.26% to -$99.1 million in 2026.
  • According to Business Quant data, Profit After Tax over the past three periods came in at -$99.1 million, -$108.0 million, and -$103.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.